This report will provide in depth knowledge of the deal making activity during 2005:
- Want to know what your competitors are doing?
- Want to benchmark your deals against others in your therapeutic area?
- See how the finances of different deal types compare?
- Want to know what the early, clinical and late stage developments are?
- Interested in new merger and acquisition activity over 2005?
- Curious about financing investments from lead investors?
Partneringreview brings all the year's deals into focus in one place.
|
Additional InformationScope of report:
- fully categorized overviews of deals, alliances and financings
- financial information where disclosed
- specialized indexes including deal type, therapy area, industry sector, financials and stage of development
- an alphabetical index of company activity
- interactive PDF format for easy exploration
Forecasts, projections, market estimates
This report provides a series of charts detailing market trends in deal making over the period of 2004 and 2005.
All the year's deals at a glance.
Partnering
review is a comprehensive summary of the year's deal announcements in a clear and accessible printable format. Every deal entry includes financial information where disclosed, such as headline values and upfront and milestone payments. A new addition of an overview of financings from investors is also included in this latest edition.
Partnering
review 2006 is the full report of all the deals data collected in 2005, providing a broad perspective of deal announcements, and incorporates all six volumes.
Volume 1: Company deal index
A comprehensive overview listing deals by company, with a full index of all the deals including mergers, acquisitions and financings announced in 2005. A clear and easy way to see the activities of any company.
Volume 2: Therapy area
Deals by fourteen therapeutic sectors, from autoimmune disease to trauma, with
classification by industry sector, deal type and stage of development.
Volume 3: Financings
A review of financing deals detailing investment information in the form of grants, awards, private financings, loans, IPOs and public offerings.
Volume 4: Stage of development
A review of deals by stage of development-appreciate how deal values change from discovery to launch.
Volume 5: Deal type
Access deal information by type of transaction-see who is licensing or partnering and using what type of deal. These are further listed by industry sector, therapy area and stage of development.
Volume 6: Industry sector
A summary of over 2,600 deal announcements by nine industry sectors, including a breakdown by therapy area, deal type and stage of development.
Who should buy the report
This report is essential reading for individuals responsible for and interested in:
- Board and executive management
- Business development
- Licensing/partnering
- Deal making
- Business strategy
- Marketing and promotion
- Distribution and manufacturing (including contract services)
Methodology
This report is derived from data obtained from Pharmalicensing's Partneringdesk deals, alliances and financings database. The database is updated daily by a team of experienced industry analysts, using industry sources including regulatory filings, press releases, company reports, company presentations.
Companies analyzed/mentioned
Other companies mentioned in the report include the top 50 biopharma: Pfizer, GlaxoSmithKline, Sanofi-Aventis, Johnson & Johnson, Merck, Novartis, AstraZeneca, Roche, Bristol-Myers Squibb, Wyeth, Abbott Labs, Eli Lilly, Amgen, Takeda, Boehringer Ingelheim, Schering-Plough, Schering AG, Bayer, Eisai, Teva, Merck KGaA, Yamanouchi, Otsuka, Novo Nordisk, Baxter, Fujisawa, Sankyo, Forest Labs, Akzo Nobel, Altana, Serono, Solvay, UCB, Genzyme, Allergan, Mitsubishi Pharma, Shionogi, Watson, IVAX, Alcon, H Lundbeck, Biogen Idec, Mylan Labs, Shire, Ono, Tanabe Seiyaku, Daiichi, Barr, Gilead Sciences, Purdue Pharma.
INTRODUCTION
About Partneringreview
Full contents of Partneringreview 2006
Deal overview in 2005
VOLUME 1: COMPANY DEAL INDEX
Introduction: Deals announced by company
Chapter 1:
Deals by company
Chapter 2: M&A by company
Chapter 3: List of deals
VOLUME 2: THERAPY AREA
Introduction: Deals announced by therapy area
Chapter 1: Oncology
Deals in the oncology therapy area by company
Deals in the oncology therapy area by industry focus
Deals in the oncology therapy area by development stage
Chapter 2: Infectious disease
Deals in the infectious disease therapy area by company
Deals in the infectious disease therapy area by industry focus
Deals in the infectious disease therapy area by development stage
Chapter 3: Cardiovascular/Circulatory
Deals in the cardiovascular/circulatory therapy area by company
Deals in the cardiovascular/circulatory therapy area by industry focus
Deals in the cardiovascular/circulatory therapy area by development stage
Chapter 4: Central Nervous System
Deals in the central nervous system therapy area by company
Deals in the central nervous system therapy area by industry focus
Deals in the central nervous system therapy area by development stage
Chapter 5: Autoimmune/Inflammation
Deals in the autoimmune/inflammation therapy area by company
Deals in the autoimmune/inflammation therapy area by industry focus
Deals in the autoimmune/inflammation therapy area by development stage
Chapter 6: Metabolism
Deals in the metabolism therapy area by company
Deals in the metabolism therapy area by industry focus
Deals in the metabolism therapy area by development stage
Chapter 7: Respiratory
Deals in the respiratory therapy area by company
Deals in the respiratory therapy area by industry focus
Deals in the respiratory therapy area by development stage
Chapter 8: Gastrointestinal
Deals in the gastrointestinal therapy area by company
Deals in the gastrointestinal therapy area by industry focus
Deals in the gastrointestinal therapy area by development stage
Chapter 9: Musculoskeletal
Deals in the musculoskeletal therapy area by company
Deals in the musculoskeletal therapy area by industry focus
Deals in the musculoskeletal therapy area by development stage
Chapter 10: Sensory Organ/Oral Health
Deals in the sensory organ/oral health therapy area by company
Deals in the sensory organ/oral health therapy area by industry focus
Deals in the sensory organ/oral health therapy area by development stage
Chapter 11: Genitourinary/Gynecology
Deals in the genitourinary/gynecology therapy area by company
Deals in the genitourinary/gynecology therapy area by industry focus
Deals in the genitourinary/gynecology therapy area by development stage
Chapter 12: Dermatology
Deals in the dermatology therapy area by company
Deals in the dermatology therapy area by industry focus
Deals in the dermatology therapy area by development stage
Chapter 13: Blood/Lymphatic System
Deals in the blood/lymphatic system therapy area by company
Deals in the blood/lymphatic system therapy area by industry focus
Deals in the blood/lymphatic system therapy area by development stage
Chapter 14: Accident/Hospital/Trauma
Deals in the accident/hospital/trauma therapy area by company
Deals in the accident/hospital/trauma therapy area by industry focus
Deals in the accident/hospital/trauma therapy area by development stage
Chapter 15: List of deals
VOLUME 3: FINANCINGS
Introduction: Deals announced by financing type
Chapter 1: Grant/award
Deals in the financing - grant/award area by company
Deals in the financing - grant/award area by therapy focus
Deals in the financing - grant/award area by development stage
Chapter 2: Equity investment
Deals in the equity investment area by company by development stage
Chapter 3: Private placement
Deals in the financing - private placement area by company
Chapter 4: IPO
Deals in the financing - IPO area by company
Chapter 5: Public offering
Deals in the financing - public offering area by company
Chapter 6: List of deals
VOLUME 4: STAGE OF DEVELOPMENT
Introduction: Deals announced by development stage
Chapter 1: Early stage - discovery, lead and preclinical
Deals in early stage by company
Deals in early stage by industry focus
Deals in early stage by therapy focus
Chapter 2: Clinical stage - phase I to Phase III
Deals in clinical stage by company
Deals in clinical stage by industry focus
Deals in clinical stage by therapy focus
Chapter 3: Late stage - registration, approval and marketed
Deals in late stage by company
Deals in late stage by industry focus
Deals in late stage by therapy focus
Chapter 4: List of deals
VOLUME 5: Deal type
Introduction: Deals announced by type
Chapter 1: Licensing
Deals in licensing by company
Deals in licensing by industry focus
Deals in licensing by therapy focus
Deals in licensing by development stage
Chapter 2: Marketing and promotion
Deals in marketing and promotion by company
Deals in marketing and promotion by industry focus
Deals in marketing and promotion by therapy focus
Deals in marketing and promotion by development stage
Chapter 3: Supply and distribution
Deals in supply and distribution by company
Deals in supply and distribution by industry focus
Deals in supply and distribution by therapy focus
Deals in supply and distribution by development stage
Chapter 4: Collaborative R&D
Deals in collaborative R&D by company
Deals in collaborative R&D by industry focus
Deals in collaborative R&D by therapy focus
Deals in collaborative R&D by development stage
Chapter 5: List of deals
VOLUME 6: INDUSTRY SECTOR
Introduction: Deals announced by industry sector
Chapter 1: Pharmaceutical
Deals in the pharmaceutical sector by company
Deals in the pharmaceutical sector by therapy focus
Deals in the pharmaceutical sector by development stage
Chapter 2: Biotechnology
Deals in the biotechnology sector by company
Deals in the biotechnology sector by therapy focus
Deals in the biotechnology sector by development stage
Chapter 3: Discovery
Deals in the discovery sector by company
Deals in the discovery sector by therapy focus
Deals in the discovery sector by development stage
Chapter 4: Research Tools
Deals in the research tools sector by company
Deals in the research tools sector by therapy focus
Deals in the research tools sector by development stage
Chapter 5: Diagnostic
Deals in the diagnostic sector by company
Deals in the diagnostic sector by therapy focus
Deals in the diagnostic sector by development stage
Chapter 6: Medical device
Deals in the medical device sector by company
Deals in the medical device sector by therapy focus
Deals in the medical device sector by development stage
Chapter 7: Bioinformatics
Deals in the bioinformatics sector by company
Deals in the bioinformatics sector by therapy focus
Deals in the bioinformatics sector by development stage
Chapter 8: Drug delivery
Deals in the drug delivery sector by company
Deals in the drug delivery sector by therapy focus
Deals in the drug delivery sector by development stage
Chapter 9: Academic/Government
Deals in the academic/government sector by company
Deals in the academic/government sector by therapy focus
Deals in the academic/government sector by development stage
Chapter 10: List of deals
GLOSSARY
List of tables, charts
VOLUME 1
Figures
Figure i.1 Partnering announcements by company 2004 vs 2005
Figure i.2 Top 25 pharma deal activity 2004 vs 2005
VOLUME 2
Tables
Table 1 Top oncology area dealmaking companies in 2005
Table 2 Top infectious disease area dealmaking companies in 2005
Table 3 Top cardiovascular/circulatory area dealmaking companies in 2005
Table 4 Top central nervous system area dealmaking companies in 2005
Table 5 Top autoimmune/inflammation area dealmaking companies in 2005
Table 6 Top metabolism area dealmaking companies in 2005
Table 7 Top respiratory area dealmaking companies in 2005
Table 8 Top gastrointestinal area dealmaking companies in 2005
Table 9 Top musculoskeletal area dealmaking companies in 2005
Table 10 Top sensory organ/oral health area dealmaking companies in 2005
Table 11 Top genitourinary/gynecology area dealmaking companies in 2005
Table 12 Top dermatology area dealmaking companies in 2005
Table 13 Top blood/lymphatic system area dealmaking companies in 2005
Table 14 Top accident/hospital/trauma area dealmaking companies in 2005
Figures
Fig. i.1 Deals announced by therapy focus
Fig. 1.1 Announcements in the oncology therapy area by company
Fig. 1.2 Announcements in the oncology therapy area by industry sector
Fig. 1.3 Announcements in the oncology therapy area by development stage
Fig. 2.1 Announcements in the infectious disease therapy area by company
Fig. 2.2 Announcements in the infectious disease therapy area by industry sector
Fig. 2.3 Announcements in the infectious disease therapy area by development stage
Fig. 3.1 Announcements in the cardiovascular/circulatory therapy area by company
Fig. 3.2 Announcements in the cardiovascular/circulatory therapy area by industry sector
Fig. 3.3 Announcements in the cardiovascular/circulatory therapy area by development
Fig. 4.1 Announcements in the central nervous system therapy area by company
Fig. 4.2 Announcements in the central nervous system therapy area by industry sector
Fig. 4.3 Announcements in the central nervous system therapy area by development stage
Fig. 5.1 Announcements in the autoimmune/inflammation therapy area by company
Fig. 5.2 Announcements in the autoimmune/inflammation therapy area by industry sector
Fig. 5.3 Announcements in the autoimmune/inflammation therapy area by development stage
Fig. 6.1 Announcements in the metabolism therapy area by company
Fig. 6.2 Announcements in the metabolism therapy area by industry sector
Fig. 6.3 Announcements in the metabolism therapy area by development stage
Fig. 7.1 Announcements in the respiratory therapy area by company
Fig. 7.2 Announcements in the respiratory therapy area by industry sector
Fig. 7.3 Announcements in the respiratory therapy area by development stage
Fig. 8.1 Announcements in the gastrointestinal therapy area by company
Fig. 8.2 Announcements in the gastrointestinal therapy area by industry sector
Fig. 8.3 Announcements in the gastrointestinal therapy area by development stage
Fig. 9.1 Announcements in the musculoskeletal therapy area by company
Fig. 9.2 Announcements in the musculoskeletal therapy area by industry sector
Fig. 9.3 Announcements in the musculoskeletal therapy area by development stage
Fig. 10.1 Announcements in the sensory organ/oral health therapy area by company
Fig. 10.2 Announcements in the sensory organ/oral health therapy area by industry sector
Fig. 10.3 Announcements in the sensory organ/oral health therapy area by development
Fig. 11.1 Announcements in the genitourinary/gynecology therapy area by company
Fig. 11.2 Announcements in the genitourinary/gynecology therapy area by industry sector
Fig. 11.3 Announcements in the genitourinary/gynecology therapy area by development
Fig. 12.1 Announcements in the dermatology therapy area by company
Fig. 12.2 Announcements in the dermatology therapy area by industry sector
Fig. 12.3 Announcements in the dermatology therapy area by development stage
Fig. 13.1 Announcements in the blood/lymphatic system therapy area by company
Fig. 13.2 Announcements in the blood/lymphatic system therapy area by industry sector
Fig. 13.3 Announcements in the blood/lymphatic system therapy area by development stage
Fig. 14.1 Announcements in the accident/hospital/trauma therapy area by company
Fig. 14.2 Announcements in the accident/hospital/trauma therapy area by industry sector
Fig. 14.3 Announcements in the accident/hospital/trauma therapy area by development
VOLUME 3
Tables
Table 1 Top financing - grant/award type dealmaking companies in 2005
Table 2 Top equity investment type dealmaking companies in 2005
Table 3 Top financing - private placement type dealmaking companies in 2005
Table 4 Top financing - IPO type dealmaking companies in 2005
Table 5 Top financing - public offering type dealmaking companies in 2005
Figures
Fig. i.1 Financing deals announced by type
Fig. 1.1 Financing - Grant/Award deals by lead investor
Fig. 1.2 Financing - Grant/Award deals by therapy area
Fig. 1.3 Financing - Grant/Award deals by development stage
VOLUME 4
Tables
Table 1 Top early stage type dealmaking companies in 2005
Table 2 Top clinical stage type dealmaking companies in 2005
Table 3 Top late stage type dealmaking companies in 2005
Figures
Fig. i.1 Deals announced by stage
Fig. 1.1 Announcements in early stage by company
Fig. 1.2 Announcements in early stage by industry sector
Fig. 1.3 Announcements in early stage by therapy area
Fig. 2.1 Announcements in clinical stage by company
Fig. 2.2 Announcements in clinical stage by industry sector
Fig. 2.3 Announcements in clinical stage by therapy area
Fig. 3.1 Announcements in late stage by company
Fig. 3.2 Announcements in late stage by industry sector
Fig. 3.3 Announcements in late stage by therapy area
VOLUME 5
Tables
Table 1 Top licensing type dealmaking companies in 2005
Table 2 Top marketing and promotion type dealmaking companies in 2005
Table 3 Top supply and distribution type dealmaking companies in 2005
Table 4 Top collaborative R&D type dealmaking companies in 2005
Figures
Fig. i.1 Deals announced by type
Fig. 1.1 Announcements of type licensing by company
Fig. 1.2 Announcements of type licensing by industry sector
Fig. 1.3 Announcements of type licensing by therapy area
Fig. 1.4 Announcements of type licensing by stage of development
Fig. 2.1 Announcements of type marketing and promotion by company
Fig. 2.2 Announcements of type marketing and promotion by industry sector
Fig. 2.3 Announcements of type marketing and promotion by therapy area
Fig. 2.4 Announcements of type marketing and promotion by stage of development
Fig. 3.1 Announcements of type supply and distribution by company
Fig. 3.2 Announcements of type supply and distribution by industry sector
Fig. 3.3 Announcements of type supply and distribution by therapy area
Fig. 3.4 Announcements of type supply and distribution by stage of development
Fig. 4.1 Announcements of type collaborative R&D by company
Fig. 4.2 Announcements of type collaborative R&D by industry sector
Fig. 4.3 Announcements of type collaborative R&D by therapy area
Fig. 4.4 Announcements of type collaborative R&D by stage of development
VOLUME 6
Tables
Table 1 Top pharmaceutical sector dealmaking companies in 2005
Table 2 Top biotechnology sector dealmaking companies in 2005
Table 3 Top discovery sector dealmaking companies in 2005
Table 4 Top research tools sector dealmaking companies in 2005
Table 5 Top diagnostic sector dealmaking companies in 2005
Table 6 Top medical device sector dealmaking companies in 2005
Table 7 Top bioinformatics sector dealmaking companies in 2005
Table 8 Top drug delivery sector dealmaking companies in 2005
Table 9 Top academic/government sector dealmaking companies in 2005
Figures
Fig. i.1 Deals announced by sector
Fig. 1.1 Announcements in the pharmaceutical sector by company
Fig. 1.2 Announcements in the pharmaceutical sector by therapy area
Fig. 1.3 Announcements in the pharmaceutical sector by stage of development
Fig. 2.1 Announcements in the biotechnology sector by company
Fig. 2.2 Announcements in the biotechnology sector by therapy area
Fig. 2.3 Announcements in the biotechnology sector by stage of development
Fig. 3.1 Announcements in the discovery sector by company
Fig. 3.2 Announcements in the discovery sector by therapy area
Fig. 3.3 Announcements in the discovery sector by stage of development
Fig. 4.1 Announcements in the research tools sector by company
Fig. 4.2 Announcements in the research tools sector by therapy area
Fig. 4.3 Announcements in the research tools sector by stage of development
Fig. 5.1 Announcements in the diagnostic sector by company
Fig. 5.2 Announcements in the diagnostic sector by therapy area
Fig. 5.3 Announcements in the diagnostic sector by stage of development
Fig. 6.1 Announcements in the medical device sector by company
Fig. 6.2 Announcements in the medical device sector by therapy area
Fig. 6.3 Announcements in the medical device sector by stage of development
Fig. 7.1 Announcements in the bioinformatics sector by company
Fig. 7.2 Announcements in the bioinformatics sector by therapy area
Fig. 7.3 Announcements in the bioinformatics sector by stage of development
Fig. 8.1 Announcements in the drug delivery sector by company
Fig. 8.2 Announcements in the drug delivery sector by therapy area
Fig. 8.3 Announcements in the drug delivery sector by stage of development
Fig. 9.1 Announcements in the academic/government sector by company
Fig. 9.2 Announcements in the academic/government sector by therapy area
Fig. 9.3 Announcements in the academic/government sector by stage of development
